Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

>2 years ≤5 visits Confirmation phase (III)No Placebo Investigational Medicines InjectionCardiology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Rapiscan

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Adenosine

Adenosine is a substance that quickly restores normal heart rhythm during certain types of rapid heartbeats.

Regadenoson

Regadenoson is a substance used during heart stress tests to temporarily increase blood flow and help detect coronary artery blockages.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Syn2

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Turku University Hospital

Turku PET Centre

Turku, Finland

Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum

Nuclear Medicine

Bad Oeynhausen, Germany

Philipps-Universitaet Marburg

Nuclear Medicine

Marburg an der Lahn, Germany

Sponsor: Synektik S.A.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.